DOP2014000241A - USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA - Google Patents

USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA

Info

Publication number
DOP2014000241A
DOP2014000241A DO2014000241A DO2014000241A DOP2014000241A DO P2014000241 A DOP2014000241 A DO P2014000241A DO 2014000241 A DO2014000241 A DO 2014000241A DO 2014000241 A DO2014000241 A DO 2014000241A DO P2014000241 A DOP2014000241 A DO P2014000241A
Authority
DO
Dominican Republic
Prior art keywords
intrauterine
contraception
well
4in3onas
systems containing
Prior art date
Application number
DO2014000241A
Other languages
English (en)
Inventor
Norbert Schmees
Henriikka Korolainen
Reinhard Nubbemeyer
Lars Röse
Tuula Valo
Katja Prelle
Harri Jukarainen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2014000241A publication Critical patent/DOP2014000241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe el uso intrauterino de 18–metil–15ß,16ߖmetilen–19–nor–20–espirox–4–en–3–onas de la fórmula general (1) fórmula (1) en la anticoncepción la terapia ginecológica, así como un sistema intrauterino que contiene compuestos de la fórmula 1.
DO2014000241A 2012-04-23 2014-10-23 USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA DOP2014000241A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012206652 2012-04-23

Publications (1)

Publication Number Publication Date
DOP2014000241A true DOP2014000241A (es) 2014-12-31

Family

ID=48142002

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000241A DOP2014000241A (es) 2012-04-23 2014-10-23 USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA

Country Status (28)

Country Link
US (1) US20150065472A1 (es)
EP (1) EP2841074A1 (es)
JP (1) JP2015514791A (es)
KR (1) KR20150004807A (es)
CN (1) CN104254333A (es)
AR (1) AR090799A1 (es)
AU (1) AU2013254840A1 (es)
BR (1) BR112014026193A2 (es)
CA (1) CA2871003A1 (es)
CL (1) CL2014002836A1 (es)
CO (1) CO7111255A2 (es)
CR (1) CR20140490A (es)
CU (1) CU20140121A7 (es)
DO (1) DOP2014000241A (es)
EA (1) EA201491922A1 (es)
EC (1) ECSP14024250A (es)
HK (1) HK1205000A1 (es)
IL (1) IL235095A0 (es)
IN (1) IN2014DN07839A (es)
MA (1) MA37444A1 (es)
MX (1) MX2014012849A (es)
PE (1) PE20142438A1 (es)
PH (1) PH12014502372A1 (es)
SG (1) SG11201406582XA (es)
TN (1) TN2014000444A1 (es)
TW (1) TW201350122A (es)
UY (1) UY34758A (es)
WO (1) WO2013160213A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015055789A1 (en) * 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
KR100913910B1 (ko) * 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
CN101001631B (zh) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
DE102007063495A1 (de) * 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
PL403688A1 (pl) * 2010-11-08 2014-02-17 Hll Lifecare Limited Wkladka wewnatrzmaciczna z kontrolowanym uwalnianiem miedzi oraz metoda przygotowywania wkladki copper-T powleczonej cienka warstewka biodegradowalna

Also Published As

Publication number Publication date
CU20140121A7 (es) 2014-12-26
IL235095A0 (en) 2014-12-31
PE20142438A1 (es) 2015-02-01
US20150065472A1 (en) 2015-03-05
CA2871003A1 (en) 2013-10-31
CL2014002836A1 (es) 2015-03-13
AR090799A1 (es) 2014-12-10
JP2015514791A (ja) 2015-05-21
MX2014012849A (es) 2015-02-05
IN2014DN07839A (es) 2015-04-24
ECSP14024250A (es) 2015-12-31
TW201350122A (zh) 2013-12-16
CN104254333A (zh) 2014-12-31
TN2014000444A1 (en) 2016-03-30
SG11201406582XA (en) 2014-11-27
PH12014502372A1 (en) 2015-01-26
UY34758A (es) 2013-11-29
AU2013254840A1 (en) 2014-11-06
CO7111255A2 (es) 2014-11-10
CR20140490A (es) 2014-11-17
MA37444A1 (fr) 2016-11-30
BR112014026193A2 (pt) 2017-06-27
HK1205000A1 (en) 2015-12-11
EA201491922A1 (ru) 2015-04-30
WO2013160213A1 (de) 2013-10-31
EP2841074A1 (de) 2015-03-04
KR20150004807A (ko) 2015-01-13

Similar Documents

Publication Publication Date Title
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UY35500A (es) Indazoles sustituidos con heteroarilo
CR20150629A (es) Compuestos químicos
GT201400241A (es) "uso de pro-fungicidas de uk-2a para el control de la sigatoka negra"
UY35943A (es) 5-flúor-4-imino-3-(alquil/alquilo sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona y los procesos para su preparación
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO6640285A2 (es) 5-alquinil-pirimidinas
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
BR112015030308A2 (pt) antagonistas de progesterona de imidazolila
DOP2016000089A (es) Sistema de administracion intrauterina
CO7350653A2 (es) Retinoides y uso de los mismos
MX369290B (es) Inhibidores de fbx03.
BR112016005972A2 (pt) plataforma semisubmersível equipada com um sistema de amplificação angular
CO7111255A2 (es) Uso intrauterino de 18-metil-15ß,16ß-,etilen-19-nor-20-espirox-4-en-3-onas, sistemas intrauterinos que contienen 18-metil-15ß,16ß-metilen-19-nor-20-espirox-4-en-3-onas, así como su uso en la anticon-cepción y terapia ginecológica
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t
BR102014007923A8 (pt) sistema nanoestruturado polimérico e seu uso
UA89388U (ru) Применение глюкозамина гидрохлорида как средства, защищающего организм от системного воздействия высоких температур
AR098060A1 (es) Sistema de administración intrauterina